Before we get to the good stuff, a few definitions.

What exactly is a syndicate, and how is it different from traditional venture funds?

Well, I’m so glad you asked :)

In a traditional venture fund, Limited Partners (LPs) commit capital upfront. The fund’s GPs then have the fun task of deciding which companies get investments out of that fund.

In typical “fund math”, the GPs expect that most of those companies will fail, some will meander, and a chosen few will have outsized returns - enough that they can “return the fund” several times over.

In other words, they can provide a healthy multiple of the amount the LPs invested, and then some. Typically, GPs have 5-10 years to do this, although lately many have needed longer.

A syndicate works differently.

Vaark evaluates opportunities, but its members can choose whether to participate deal by deal. Tim jokingly described part of the process as “herding cats”: the syndicate has to gauge interest and assemble an allocation for each investment.

For founders, there are both benefits and tradeoffs.

A traditional fund generally has committed capital available once it decides to invest. With a syndicate, it’s worth understanding how much of the allocation is actually committed, how long syndication takes, and what follow-on support might look like.

The upside can come from the network around that check.

A specialist syndicate can draw on clinicians and operators living the problem firsthand, helping them understand and underwrite promising technology earlier, before much clinical or commercial evidence exists.

Vaark has roughly 250 members, including physicians, senior executives, operators, and SMEs across engineering, data science, regulatory affairs, IP, and other adjacent disciplines.

That’s a powerful network to help founders scale.

Which brings us to Norbert Health.

Just as I was doing research for our podcast, I decided to look up Norbert Health, one of Vaark’s early investments.

Norbert Health is building AI-powered robotic nursing assistants that autonomously collect patient vitals and support routine care in healthcare facilities.

Less than 24 hours before we sat down to record, Norbert announced a $14M Series A.

So of course, this was one of my first questions to Tim and Elizabeth.

What initially attracted Vaark to the company, and what did Norbert do after the seed round that allowed them to scale and raise their Series A?

When Tim and Elizabeth broke it down, one thing stood out: Norbert was already deployed in nursing facilities. It was not just a technology looking for a use case.

Getting a healthcare product through all the committees, approvals, workflows and procurement processes is not easy. In fact, it is really, really hard.

Norbert's ability to do it was already a moat.

And once you’re inside, another flywheel starts.

Real-world deployment generates proprietary data. That data helps improve the product. It also lets you demonstrate outcomes and ROI, which can help you win the next customer.

Norbert’s robotic hardware will continue to evolve. But its experience interacting with real patients and providers, understanding clinical workflows, and collecting data inside healthcare environments is much harder to replicate.

Founder takeaway: Don’t think about your first healthcare customer as just early revenue. Getting inside the system, learning how it works, and proving value there can become part of your competitive advantage.

For most investors, the more companies they see, the more they develop their “pattern recognition”

Through experience, they start to understand what can look great in a pitch deck but be complete fiction in the real world.

But pattern recognition can also lead to bias.

That's why Elizabeth built an intelligence framework that Vaark is working into its diligence. It scores every company against the same dimensions, like founder experience, regulatory preparedness, market timing, and other sources of risk, so very different companies can be evaluated using a common language.

Elizabeth eventually wants founders to score themselves on the same framework. If the founder rates an area a 9 and the investor rates it a 4, that gap serves as a much more specific and productive conversation, rather than usual startup platitudes.

Founder takeaway: don't wait for an investor to build a framework around your company. Build one first, and be prepared to discuss your company as a sum of its assumptions and hypotheses.

Tim often sees technical founders start building before realizing the problem isn’t painful enough.

For instance, the literature may say that a complication occurs in 10% of patients. That looks like a big market… Until you learn that only a fraction of those cases are significant enough for a physician to change their processes.

Wound care was another great example Tim brought up. Vaark invested in a company with published clinical advantages and better economics than a competing technology. Yet plenty of surgeons still reach for cheap steri-strips because they’ve worked perfectly well for twenty years.

As Elizabeth put it: “What difference does a difference make?”

A better product isn’t always enough to change behavior. And in healthcare, the person using your product often isn’t the person paying for it.

A clinician can love your software while IT, procurement, or finance blocks the purchase. Leadership can also buy something that clinicians never really adopt.

I also asked Tim and Elizabeth for tips so founders don’t get stuck in “pilot purgatory” - running pilot after pilot while never getting to actual cash flow.

Here are the questions that Tim asks whenever he sees pilots listed as traction in a pitch deck: Are they paid? What’s being measured? Who decides whether the pilot converts?

And most importantly, what happens if you hit the endpoint?

Founder Takeaway: Map who uses your product, who pays for it, and who can stop the purchase. Then find someone inside the system who can tell you whether you’ve mapped it correctly.

And before you start a pilot, agree on what happens if you hit the endpoint. A pilot without a path to conversion is much weaker evidence of traction.

Healthcare data is becoming increasingly connected through EHRs, wearables, diagnostics, biomarkers, and patient-generated data.

Tim and Elizabeth described this as part of their thesis of the “Great Convergence.”

But simply aggregating all that information adds less value than most realize.

As Elizabeth heard repeatedly from clinicians during her time in healthcare innovation:

“Don’t give me more data. Give me actionable data.”

A physician doesn’t need thousands more measurements to review and a patient doesn’t need a dashboard filled with numbers they can’t interpret.

The real value is increasingly one layer above the data: cleaning it up, putting it in context, identifying what matters, and helping someone make a better decision.

Tim sees the same shift in diagnostics. We can detect more signals than ever, but the bottleneck increasingly becomes interpretation: What does this mean for this patient, and what should we do next?

Founder takeaway: If you’re building around healthcare data, don’t stop at access or aggregation. Ask what decision your product makes easier, what action it enables, and whose behavior changes because of it.

Towards the end of the conversation, I asked Elizabeth what could truly make a company uninvestable.

Her list was surprisingly short:

Most other things can be improved.

That second point came up repeatedly throughout our conversation.

Building a healthcare company requires enormous conviction. You’re dealing with regulation, reimbursement, long sales cycles, entrenched competitors, and plenty of people telling you why something won’t work.

But conviction can eventually turn into stubbornness.

The founders who navigate that tension well seem to strike that careful balance: they know why they’re building, but they also know what they don’t know.

It’s a balance between conviction, ambition, and belief that you will succeed - paired with humility and an understanding that you don’t have all the answers.

And when the evidence tells the founders that they need to change direction, they’re willing to listen.

As Elizabeth put it: be open to the pivot.

My biggest takeaway from this conversation is that healthcare founders have to get comfortable looking beyond the technology.

Can you get inside the system? Are you solving a problem painful enough to change behavior? Can you turn a pilot into a customer? And as healthcare generates more data, can you turn that information into a decision someone can actually use?

None of these questions have easy answers, especially early on. That’s also why the right investors, operators, and advisors can be so valuable.

As Tim and Elizabeth both emphasized, you don’t need to know everything.

You need to know what you don’t know, surround yourself with people who can help, and stay open to changing course when the evidence points you somewhere better.

A huge thanks to Tim and Elizabeth for joining me.

I strongly recommend connecting with each of them via LinkedIn and exploring the additional resources below.

For the full conversation, you can watch the full episode here.

If you haven't already, hit follow on Spotify or Apple Podcasts - it genuinely helps us build momentum. And if you watch on YouTube, don't forget to subscribe and spread the word.

See you next week!

- Vadim

PS: Do you know a founder, an investor, or a subject matter expert that I should interview? If so, you know what to do 🙂

PPS: If you found this issue useful, the easiest way to support is to forward it to one founder who'd benefit. They can subscribe at biofounder.io